The reference site for Daclizumab

Daclizumab (trade name Zinbryta, by Biogen) is a therapeutic humanized monoclonal antibody used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

WHAT IS DACLIZUMAB?

Daclizumab is an immunosuppressant. It decreases the actions of the body’s immune system.

This medicine is used to prevent the body from rejecting a transplanted kidney. Daclizumab is usually used as part of a treatment regimen including other medications.

In the United Kingdom, the National Institute for Health and Clinical Excellence has recommended its use be considered for all kidney transplant recipients.

 

Brand Name(s): Zenapax
CAS nº: 152923-56-3
(dah KLIH zyoo mab)

 

Product Info

The sections below will provide you with more specific information and guidelines related to daclizumab and its correct use. Please read them carefully.

FDA Information

Daclizumab (trade name Zenapax®) received FDA approval in 1997 for use in kidney transplantation. A prescription is required for this medicine.

Please visit the official site of the FDA for further information.

Why is this medication prescribed?

Daclizumab is an immunosuppressant. Immunosuppressants decrease the actions of the body’s immune system.

This medicine is used to prevent the body from rejecting a transplanted kidney, and is usually administered as part of a treatment regimen including other medications.

In the United Kingdom, the National Institute for Health and Clinical Excellence has recommended its use be considered for all kidney transplant recipients.

Other uses for this medicine

This drug may also be used for other types of organ transplants.

Nevertheless, it is important that you talk to your doctor about the possible risks of using this drug for your particular condition.

Dosage and using this medicine

Daclizumab is administered as an intravenous (into the vein) injection. In most cases, your healthcare provider will administer daclizumab in a hospital or clinic setting. If you are using daclizumab at home, your healthcare provider will give you detailed instructions regarding preparation, administration, and storage of the medication.

The first dose of daclizumab is usually administered within 24 hours of the kidney transplant. Four additional doses are then given at 14 day intervals following transplantation.

When mixing the solution for injection, the bag should be gently inverted to ensure mixing. Do not shake the mixture.

After mixing the solution for injection, it should be used within 4 hours. If the mixture cannot be used within 4 hours, it should be refrigerated between 36 and 46 degrees Fahrenheit (2 and 8 degrees Celsius) for up to 24 hours. If it is not used within 24 hours, it must be discarded.

Do not use any solution that is discolored or that has particles in it.

Furthermore, your doctor may want you to have blood tests or other medical evaluations during treatment with daclizumab to monitor progress and side effects.

Your healthcare provider will store daclizumab as directed by the manufacturer. If you are using daclizumab at home, your healthcare provider will give you detailed storage instructions.

What special precautions should I follow?

BEFORE TAKING DACLIZUMAB:

In deciding to use a medicine, the risks of receiving the medicine must be weighed against the good it will provide. This is a decision you and your doctor will make. For daclizumab, the following should also be considered:

Allergies – Tell your doctor if you have ever had any unusual or allergic reaction to daclizumab. Also tell your health care professional if you are allergic to any other substances.

Pregnancy – Daclizumab crosses the placenta. However, daclizumab has not been studied in pregnant women.

Breast-feeding – It is not known if daclizumab passes into breast milk. Breast-feeding is not recommended for patients receiving daclizumab.

Children – Studies on the use of daclizumab in children have not been completed. However, daclizumab may cause high blood pressure and dehydration more often in children than it does in adults.

Older adults – Many medicines have not been studied specifically in older patients. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of daclizumab in the elderly with use in other age groups.

Vaccination – Talk to your doctor before receiving any vaccines during treatment with daclizumab. Some vaccines may not be effective, or may be harmful, if received during treatment with daclizumab. In addition, avoiding close contact with people who have recently been vaccinated with a “live” vaccine (e.g. oral polio vaccine, nasal influenza vaccine) may be recommended. There is a chance that the virus can be passed on to you.

Other medical problems – The presence of other medical problems may affect the use of daclizumab. Make sure you tell your doctor if you have any other medical problems, especially:
Cancer – daclizumab may make this condition worse.
Diabetes mellitus (sugar diabetes) – daclizumab can increase the amount of sugar in the blood.
Infection – daclizumab may decrease the body’s ability to fight infection.

What should I do if I forget a dose?

Contact your doctor if you miss a dose of daclizumab.

What side effects can this medication cause?

Contact your doctor immediately if you develop signs of infection such as:

fever or chills
sore throat, coughing, congestion or other signs of infection
redness, pain, or swelling of a skin wound
burning or difficult urination

Treatment with an immunosuppressant such as daclizumab may increase the risk of developing certain types of cancer (e.g., lymphoma). Talk to your doctor about the risks and benefits of using this medication.

If you experience a serious allergic reaction (difficulty breathing, closing of the throat, swelling of the lips, tongue, or face, or hives) to daclizumab, seek emergency medical attention.

Other, less serious side effects may also occur. Continue to use daclizumab and notify your doctor if you experience:

upset stomach, nausea, or vomiting
diarrhea or constipation
tremor or dizziness
headache
swelling of the hands, feet or legs

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

What storage conditions are needed for this medicine?

Your healthcare provider will store daclizumab as directed by the manufacturer. If you are using daclizumab at home, your healthcare provider will give you detailed storage instructions.

In case of an emergency/overdose

In the case of a suspected overdose, call your local poison control center on 1-800-222-1222. However, if the victim has collapsed or is not breathing then call the local emergency services immediately on 911.

Symptoms of a daclizumab overdose are not known.

Product Images

PICTURES OF DACLIZUMAB PILLS

Below you will find images and specific information on the principal types of daclizumab that exist, including their respective brand name(s), strength, inscription codes, manufacturers and/or distributors.

The information below includes general information and guidelines for patients taking this medication and should never be used to substitute professional medical advice that can be provided by a qualified physician or family doctor.

Name: ZENAPAX®
Strength(s): 25 MG / 5 ML
Imprint: Sterile Concentrate for Injection
Manufacturer: ROCHE

Contact us